

Polymorphism of Human Cytochrome P450 2D6 and Its

Clinical Pharmacokinetics

48, 689-723

DOI: 10.2165/11318030-000000000-00000

Citation Report

#	ARTICLE	IF	CITATIONS
2	Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance. <i>Clinical Pharmacokinetics</i> , 2009, 48, 761-804.	3.5	306
3	Antiepileptic Drug Interactions - Principles and Clinical Implications. <i>Current Neuropharmacology</i> , 2010, 8, 254-267.	2.9	275
4	Psychedelic 5-Methoxy-N,N-Dimethyltryptamine: Metabolism, Pharmacokinetics, Drug Interactions, and Pharmacological Actions. <i>Current Drug Metabolism</i> , 2010, 11, 659-666.	1.2	122
5	Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 611-618.	1.5	99
6	How and Why to Screen for CYP2D6 Interindividual Variability in Patients Under Pharmacological Treatments. <i>Current Drug Metabolism</i> , 2010, 11, 276-282.	1.2	39
7	Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes—focus on venlafaxine and O-desmethylenlafaxine. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 879-887.	1.9	19
8	The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 1109-1117.	1.9	80
9	Pharmacogenetics and forensic toxicology. <i>Forensic Science International</i> , 2010, 203, 53-62.	2.2	56
10	Pharmacogenetics in palliative care. <i>Forensic Science International</i> , 2010, 203, 63-70.	2.2	19
11	Hypertrophic cardiomyopathy in childhood and adolescence — strategies to prevent sudden death. <i>Fundamental and Clinical Pharmacology</i> , 2010, 24, 637-652.	1.9	55
12	Cytochrome P450-mediated hepatic metabolism of new fluorescent substrates in cats and dogs. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2010, 33, 519-527.	1.3	31
13	Effect of the CYP2D6*10 Genotype on Tolterodine Pharmacokinetics. <i>Drug Metabolism and Disposition</i> , 2010, 38, 1456-1463.	3.3	16
14	The Impact of Paroxetine Coadministration on Stereospecific Carvedilol Pharmacokinetics. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2010, 15, 373-379.	2.0	20
15	Personalized therapy in pain management: where do we stand?. <i>Pharmacogenomics</i> , 2010, 11, 843-864.	1.3	71
16	Induced pluripotent stem cells: opportunities as research and development tools in 21st century drug discovery. <i>Regenerative Medicine</i> , 2010, 5, 557-568.	1.7	25
17	Genetic Variations in Human Glutathione Transferase Enzymes: Significance for Pharmacology and Toxicology. <i>Human Genomics and Proteomics</i> , 2010, 2, 876940.	1.5	103
18	Estimation of the Interindividual Variability of Cytochrome 2D6 Activity from Urinary Metabolic Ratios in the Literature. <i>Drug Metabolism and Pharmacokinetics</i> , 2010, 25, 243-253.	2.2	19
19	New Meconium Biomarkers of Prenatal Methamphetamine Exposure Increase Identification of Affected Neonates. <i>Clinical Chemistry</i> , 2010, 56, 856-860.	3.2	14

#	ARTICLE	IF	CITATIONS
20	How Does Genetics Influence the Efficacy and Safety of Antiarrhythmic Drugs?. Cardiac Electrophysiology Clinics, 2010, 2, 359-367.	1.7	0
21	Advances in Perioperative Pain Management: Use of Medications with Dual Analgesic Mechanisms, Tramadol & Tapentadol. Anesthesiology Clinics, 2010, 28, 647-666.	1.4	45
22	Characterization of 107 Genomic DNA Reference Materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1. Journal of Molecular Diagnostics, 2010, 12, 835-846.	2.8	98
23	Risperidone long-acting injectable (Risperdal Consta [®]) for maintenance treatment in patients with bipolar disorder. Expert Review of Neurotherapeutics, 2010, 10, 1637-1658.	2.8	41
24	Effects of heme precursors on CYP1A2 and POR expression in the baculovirus/Spodoptera frugiperda system. Journal of Biomedical Research, 2010, 24, 242-249.	1.6	6
25	Genetic variations in cytochrome P450 (CYP) 2D6 activity may have important clinical consequences for some drugs. Drugs and Therapy Perspectives, 2010, 26, 21-26.	0.6	0
27	Emerging therapies in metastatic bone pain. Expert Opinion on Emerging Drugs, 2011, 16, 441-458.	2.4	15
28	Sex Differences in 3,4-Methylenedioxymethamphetamine (MDMA; Ecstasy)-Induced Cytochrome P450 2D6 Inhibition in Humans. Clinical Pharmacokinetics, 2011, 50, 319-329.	3.5	27
29	Quantitative Prediction of Cytochrome P450 (CYP) 2D6-Mediated Drug Interactions. Clinical Pharmacokinetics, 2011, 50, 519-530.	3.5	43
30	Copy number variants in pharmacogenetic genes. Trends in Molecular Medicine, 2011, 17, 244-251.	6.7	90
31	Infusion of Pharmacogenetics Into Cancer Care. Seminars in Oncology Nursing, 2011, 27, 45-53.	1.5	6
32	Pain, analgesia and genetics. Journal of Pharmacy and Pharmacology, 2011, 63, 1387-1400.	2.4	43
33	CYP2D6- and CYP3A-Dependent Enantioselective Plasma Concentrations of Ondansetron in Postanesthesia Care. Anesthesia and Analgesia, 2011, 113, 48-54.	2.2	31
34	Role of Retinoids, Rexinoids and Thyroid Hormone in the Expression of Cytochrome P450 Enzymes. Current Drug Metabolism, 2011, 12, 71-88.	1.2	49
35	Pharmacokinetics of Tolterodine in Japanese and Koreans: Physiological and Stochastic Assessment of Ethnic Differences. Drug Metabolism and Pharmacokinetics, 2011, 26, 236-241.	2.2	10
36	Clinically Relevant Genetic Variations in Drug Metabolizing Enzymes. Current Drug Metabolism, 2011, 12, 487-497.	1.2	101
37	Understanding pharmacogenomics: applications in prescribing. NursePrescribing, 2011, 9, 402-407.	0.1	1
38	The basics of pharmacokinetics in prescribing and clinical practice. NursePrescribing, 2011, 9, 557-566.	0.1	2

#	ARTICLE	IF	CITATIONS
39	Genotype-Based Quantitative Prediction of Drug Exposure for Drugs Metabolized by CYP2D6. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 582-587.	4.7	22
40	A Review of Systemic Opioids Commonly Used for Labor Pain Relief. <i>Journal of Midwifery and Women's Health</i> , 2011, 56, 222-239.	1.3	45
41	Guidance of pharmacotherapy in a complex psychiatric case by CYP450 DNA typing. <i>Journal of the American Academy of Nurse Practitioners</i> , 2011, 23, 459-463.	1.4	9
42	Effects of Paroxetine on the Pharmacokinetics and Pharmacodynamics of Immediate-Release and Extended-Release Metoprolol. <i>Pharmacotherapy</i> , 2011, 31, 630-641.	2.6	30
43	Perioperative genomics. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2011, 25, 549-555.	4.0	8
44	Pharmacogenetics and individualized therapy in children: immunosuppressants, antidepressants, anticancer and anti-inflammatory drugs. <i>Pharmacogenomics</i> , 2011, 12, 827-843.	1.3	13
45	CYP2D6 genotyping by liquid chromatography-electrospray ionization mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 400, 2361-2370.	3.7	18
46	The role of β -blockers in the management of hypertension: An Asian perspective. <i>Current Medical Research and Opinion</i> , 2011, 27, 1021-1033.	1.9	14
47	Review: Malaria Chemoprophylaxis for Travelers to Latin America. <i>American Journal of Tropical Medicine and Hygiene</i> , 2011, 85, 1015-1024.	1.4	23
48	Humanized mice with ectopic artificial liver tissues. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 11842-11847.	7.1	144
49	CYP2D6 genotyping in breast cancer patients by liquid chromatography-electrospray ionization mass spectrometry. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2011, 6, 247-53.	0.7	0
50	Predictors of Risperidone and 9-Hydroxyrisperidone Serum Concentration in Children and Adolescents. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2011, 21, 163-169.	1.3	30
52	Epidemiology and Risk Factors for (Tardive) Dyskinesia. <i>International Review of Neurobiology</i> , 2011, 98, 211-230.	2.0	42
53	Expression Profiles of Metabolic Enzymes and Drug Transporters in the Liver and along the Intestine of Beagle Dogs. <i>Drug Metabolism and Disposition</i> , 2012, 40, 1603-1611.	3.3	30
54	Genetic determinants of response to cardiovascular drugs. <i>Current Opinion in Cardiology</i> , 2012, 27, 253-261.	1.8	14
55	Prediction of CYP2D6 Drug Interactions from In Vitro Data: Evidence for Substrate-Dependent Inhibition. <i>Drug Metabolism and Disposition</i> , 2012, 40, 47-53.	3.3	65
56	Relationship between the Concentration of Hydrocodone and its Conversion to Hydromorphone in Chronic Pain Patients Using Urinary Excretion Data. <i>Journal of Analytical Toxicology</i> , 2012, 36, 257-264.	2.8	38
57	Pharmacokinetics, Safety, and Tolerability of Atomoxetine and Effect of CYP2D6*10/*10 Genotype in Healthy Japanese Men. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 388-403.	2.0	35

#	ARTICLE	IF	CITATIONS
58	Distribution of <i>CYP2D6</i> and <i>CYP2C19</i> Polymorphisms Associated with Poor Metabolizer Phenotype in Five Amerindian Groups and Western Mestizos from Mexico. Genetic Testing and Molecular Biomarkers, 2012, 16, 1098-1104.	0.7	35
59	Lessons From Pharmacogenetics and Metoclopramide. Journal of Clinical Gastroenterology, 2012, 46, 437-439.	2.2	8
61	Similarities and Differences between US and Japan as to Pharmacogenomic Biomarker Information in Drug Labels. Drug Metabolism and Pharmacokinetics, 2012, 27, 142-149.	2.2	26
62	Pharmacogenetic screening for drug therapy: From single gene markers to decision making in the next generation sequencing era. Pathology, 2012, 44, 166-180.	0.6	23
63	Inter-individual Variability of In Vivo CYP2D6 Activity in Different Genotypes. Drug Metabolism and Pharmacokinetics, 2012, 27, 405-413.	2.2	21
64	Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy"): The Influence of Gender and Genetics (CYP2D6, COMT, 5-HTT). PLoS ONE, 2012, 7, e47599.	2.5	48
65	Developments in harmine pharmacology " Implications for ayahuasca use and drug-dependence treatment. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 39, 263-272.	4.8	97
66	Pharmacogenetics of pain and analgesia. Clinical Genetics, 2012, 82, 321-330.	2.0	31
69	"Drugs on oxygen" an update and perspective on the role of cytochrome P450 testing in pharmacology. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 1357-1362.	3.3	5
70	A SNPshot of PubMed to associate genetic variants with drugs, diseases, and adverse reactions. Journal of Biomedical Informatics, 2012, 45, 842-850.	4.3	46
71	The Clinical Implications of Cytochrome P450 Interactions With Opioids and Strategies for Pain Management. Journal of Pain and Symptom Management, 2012, 44, S15-S22.	1.2	17
72	Psychiatric Pharmacogenomics in Pediatric Psychopharmacology. Child and Adolescent Psychiatric Clinics of North America, 2012, 21, 773-788.	1.9	9
73	Pharmacogenomics of Beta-Blockers and Statins: Possible Implications for Perioperative Cardiac Complications. Journal of Cardiothoracic and Vascular Anesthesia, 2012, 26, 1101-1114.	1.3	5
74	Metabolism of the Active Metabolite of Quetiapine, <i>N</i> -Desalkylquetiapine In Vitro. Drug Metabolism and Disposition, 2012, 40, 1778-1784.	3.3	28
75	Label-free genotyping of cytochrome P450 2D6*10 using ligation-mediated strand displacement amplification with DNAzyme-based chemiluminescence detection. Analytica Chimica Acta, 2012, 710, 111-117.	5.4	9
76	The right compound in the right assay at the right time: an integrated discovery DMPK strategy. Drug Metabolism Reviews, 2012, 44, 224-252.	3.6	51
77	CYP2D6 gene variants in urban/admixed and Amerindian populations of Venezuela: Pharmacogenetics and anthropological implications. Annals of Human Biology, 2012, 39, 137-142.	1.0	21
78	Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy. Genetics in Medicine, 2012, 14, 990-1000.	2.4	39

#	ARTICLE	IF	CITATIONS
79	Safety of Flecainide. Drug Safety, 2012, 35, 273-289.	3.2	29
80	An Introduction to Personalized Medicine. , 2012, , 121-142.		3
81	Regioselective biotransformation of CNS drugs and its clinical impact on adverse drug reactions. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 833-854.	3.3	12
83	Meclizine Metabolism and Pharmacokinetics: Formulation on Its Absorption. Journal of Clinical Pharmacology, 2012, 52, 1343-1349.	2.0	32
84	Fluoxetine pharmacogenetics in child and adult populations. European Child and Adolescent Psychiatry, 2012, 21, 599-610.	4.7	30
85	Drug Interactions with Triptans. CNS Drugs, 2012, 26, 949-957.	5.9	24
86	Functional Characterization of a First Avian Cytochrome P450 of the CYP2D Subfamily (CYP2D49). PLoS ONE, 2012, 7, e38395.	2.5	10
87	Determination of Cytochrome P450 Metabolic Activity Using Selective Markers. , 0, , .		9
88	Pharmacogenomic considerations in opioid analgesia. Pharmacogenomics and Personalized Medicine, 2012, 5, 73.	0.7	26
89	Biomarkers and Therapeutic Drug Monitoring in Psychiatry. , 0, , .		3
90	Pharmacogenomics-Guided Approaches to Avoiding Adverse Drug Reactions. Clinical Pharmacology & Biopharmaceutics, 2012, 01, .	0.2	2
91	â€œOmicâ€™ Genetic Technologies for Herbal Medicines in Psychiatry. Phytotherapy Research, 2012, 26, 522-527.	5.8	17
92	Copy number variation and gene rearrangements in CYP2D6 genotyping using multiplex ligation-dependent probe amplification in Koreans. Pharmacogenomics, 2012, 13, 963-973.	1.3	10
93	The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers. Cancer Chemotherapy and Pharmacology, 2012, 69, 991-997.	2.3	25
94	Host factors affecting antiepileptic drug deliveryâ€™ Pharmacokinetic variability. Advanced Drug Delivery Reviews, 2012, 64, 896-910.	13.7	92
95	Fraud or flawed ? At the end of the day it may be the patient who pays the bill !. Clinical Therapeutics, 2012, 34, 1204-1206.	2.5	2
96	Differences in genotype and allele frequency distributions of polymorphic drug metabolizing enzymes CYP2C19 and CYP2D6 in mainland Chinese Mongolian, Hui and Han populations. Journal of Clinical Pharmacy and Therapeutics, 2012, 37, 364-369.	1.5	28
97	Serum dextromethorphan/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice. Journal of Clinical Pharmacy and Therapeutics, 2012, 37, 486-490.	1.5	21

#	ARTICLE	IF	CITATIONS
98	Usefulness of postmortem biochemistry in forensic pathology: Illustrative case reports. Legal Medicine, 2012, 14, 27-35.	1.3	32
99	Molecular docking and enzyme kinetic studies of dihydrotanshinone on metabolism of a model CYP2D6 probe substrate in human liver microsomes. Phytomedicine, 2012, 19, 648-657.	5.3	10
100	Liver kidney microsomal type 1 antibodies reduce the CYP2D6 activity in patients with chronic hepatitis C virus infection. Journal of Viral Hepatitis, 2012, 19, 568-573.	2.0	16
101	Polymorphisms of the GSTM1, GSTT1, and CYP2D6 xenobiotic biotransformation genes, which are possible risk markers of cancer in populations of indigenous ethnic groups and Russians of North Siberia. Russian Journal of Genetics: Applied Research, 2012, 2, 7-17.	0.4	10
102	Mice with artificial human liver. Hepatology, 2012, 55, 974-977.	7.3	0
103	Advances in Molecular Modeling of Human Cytochrome P450 Polymorphism. Journal of Molecular Biology, 2013, 425, 3978-3992.	4.2	39
104	Pharmacogenetics and Pharmacogenomics. , 2013, , 1-27.		0
105	Toxicogeneticsâ€”cytochrome P450 microarray analysis in forensic cases focusing on morphine/codeine and diazepam. International Journal of Legal Medicine, 2013, 127, 395-404.	2.2	14
106	Population Pharmacokinetics of Carvedilol in Patients with Congestive Heart Failure. Journal of Pharmaceutical Sciences, 2013, 102, 2851-2858.	3.3	10
107	The evolution of our understanding of endo-xenobiotic crosstalk and cytochrome P450 regulation and the therapeutic implications. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 1541-1554.	3.3	18
108	A Meta-Analysis of CYP2D6 Metabolizer Phenotype and Metoprolol Pharmacokinetics. Clinical Pharmacology and Therapeutics, 2013, 94, 394-399.	4.7	101
109	Polymorphisms and phenotypic analysis of cytochrome P450 2D6 in the Tibetan population. Gene, 2013, 527, 360-365.	2.2	14
110	Selective inhibition of the cytochrome P450 isoform by hyperoside and its potent inhibition of CYP2D6. Food and Chemical Toxicology, 2013, 59, 549-553.	3.6	30
111	Cytochrome p450, Part 1. Nursing Clinics of North America, 2013, 48, 671-680.	1.5	7
112	Cytochrome p450 Part 2. Nursing Clinics of North America, 2013, 48, 681-696.	1.5	7
113	Role of Cytochrome P450 Isoenzymes 3A and 2D6 in the In Vivo Metabolism of Mirabegron, a Î²3-Adrenoceptor Agonist. Clinical Drug Investigation, 2013, 33, 429-440.	2.2	31
114	What is the role of pharmacogenetics in clinical psychiatry?. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 1-4.	3.3	9
115	The interplay between environmental and genetic factors in Parkinson's disease susceptibility: The evidence for pesticides. Toxicology, 2013, 307, 17-23.	4.2	95

#	ARTICLE	IF	CITATIONS
116	Cocaine in sudden and unexpected death: A review of 49 post-mortem cases. Forensic Science International, 2013, 227, 52-59.	2.2	48
117	“How High Do They Look?” Identification and Treatment of Common Ingestions in Adolescents. Journal of Pediatric Health Care, 2013, 27, 135-144.	1.2	44
118	Pharmacodynamic, Pharmacokinetic and Pharmacogenetic Aspects of Drugs Used in the Treatment of Alzheimer’s Disease. Clinical Pharmacokinetics, 2013, 52, 225-241.	3.5	156
119	Developmental expression of drug metabolizing enzymes: Impact on disposition in neonates and young children. International Journal of Pharmaceutics, 2013, 452, 3-7.	5.2	137
120	Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer. Expert Review of Molecular Diagnostics, 2013, 13, 349-365.	3.1	22
121	Characterization of the <i>CYP2D6</i> gene locus and metabolic activity in Indo- and Afro-Trinidadians: discovery of novel allelic variants. Pharmacogenomics, 2013, 14, 261-276.	1.3	42
122	Tramadol-induced apnea. American Journal of Emergency Medicine, 2013, 31, 26-31.	1.6	52
123	The Association of CYP2D6 Genotype and Postoperative Nausea and Vomiting in Orthopedic Trauma Patients. Biological Research for Nursing, 2013, 15, 382-389.	1.9	31
124	Complexities of <i>CYP2D6</i> gene analysis and interpretation. International Review of Psychiatry, 2013, 25, 534-553.	2.8	188
125	Genetic variations of human <i>CYP2D6</i> in the Chinese Han population. Pharmacogenomics, 2013, 14, 1731-1743.	1.3	54
126	A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer. Cancer Chemotherapy and Pharmacology, 2013, 72, 747-755.	2.3	14
127	The effects of typical and atypical antipsychotics on the electrical activity of the brain in a rat model. Journal of Clinical and Experimental Investigations, 2013, 4, .	0.3	1
128	Importance of pharmacogenetics in the treatment of children with attention deficit hyperactive disorder: a case report. Pharmacogenomics and Personalized Medicine, 2013, 6, 3.	0.7	3
129	Cytochrome P450-mediated drug metabolism in the brain. Journal of Psychiatry and Neuroscience, 2013, 38, 152-163.	2.4	103
130	Relationship of CYP2D6, CYP3A, POR, and ABCB1 Genotypes With Galantamine Plasma Concentrations. Therapeutic Drug Monitoring, 2013, 35, 270-275.	2.0	27
131	Genetic variants in the cytochrome P450 2D6 gene in the Sri Lankan population. Indian Journal of Human Genetics, 2013, 19, 392.	0.7	8
132	Recent examples on the clinical relevance of the CYP2D6 polymorphism and endogenous functionality of CYP2D6. Drug Metabolism and Drug Interactions, 2013, 28, 209-216.	0.3	16
133	Relationship between <i>CYP2D6</i> genotype and haloperidol pharmacokinetics and extrapyramidal symptoms in healthy volunteers. Pharmacogenomics, 2013, 14, 1551-1563.	1.3	16

#	ARTICLE	IF	CITATIONS
134	Pharmacogenetics of analgesic drugs. British Journal of Pain, 2013, 7, 189-208.	1.5	42
135	Systematic Functional Study of Cytochrome P450 2D6 Promoter Polymorphisms in the Chinese Han Population. PLoS ONE, 2013, 8, e57764.	2.5	5
136	CYP2D6 Genotype Dependent Oxycodone Metabolism in Postoperative Patients. PLoS ONE, 2013, 8, e60239.	2.5	64
137	Update on prescription extended-release opioids and appropriate patient selection. Journal of Multidisciplinary Healthcare, 2013, 6, 265.	2.7	17
138	Metabolism and pharmacokinetic optimization strategies in drug discovery. , 2013, , 135-155.		3
139	Antidepressant Tolerability and Potential Clinical Implications of Serotonin-2A Genotypes. Clinical Pharmacology & Biopharmaceutics, 2013, 02, .	0.2	0
140	Possible impact of the CYP2D6*10 polymorphism on the nonlinear pharmacokinetic parameter estimates of paroxetine in Japanese patients with major depressive disorders. Pharmacogenomics and Personalized Medicine, 2014, 7, 121.	0.7	8
141	Autism Spectrum Disorders: An Intervention Approach Based on Genomic Analysis. Biology and Medicine (Aligarh), 2014, 01, .	0.3	1
142	PGx/Biomarker Utilization for Regulatory Decision Making. , 2014, , 951-967.		1
143	The clinical and public health problem of relapse despite primaquine therapy: case review of repeated relapses of Plasmodium vivax acquired in Papua New Guinea. Malaria Journal, 2014, 13, 488.	2.3	51
144	CYP2D6 gene polymorphisms and predicted phenotypes in eight indigenous groups from northwestern Mexico. Pharmacogenomics, 2014, 15, 339-348.	1.3	28
145	Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics. Pharmacogenomics, 2014, 15, 1947-1962.	1.3	39
146	Frequency of CYP450 enzyme gene polymorphisms in the Greek population: review of the literature, original findings and clinical significance. Drug Metabolism and Drug Interactions, 2014, 29, 235-248.	0.3	12
147	In Silico Study on the Inhibitory Interaction of Drugs with Wild-type CYP2D6.1 and the Natural Variant CYP2D6.17. Drug Metabolism and Pharmacokinetics, 2014, 29, 52-60.	2.2	14
148	Influence of Cytochrome P450, Family 2, Subfamily D, Polypeptide 6 (CYP2D6) Polymorphisms on Pain Sensitivity and Clinical Response to Weak Opioid Analgesics. Drug Metabolism and Pharmacokinetics, 2014, 29, 29-43.	2.2	35
149	Correlation between CYP2D6*10 Gene Mutation, and Structure and Function of its Encoding Prot. Tropical Journal of Pharmaceutical Research, 2014, 13, 347.	0.3	0
150	Personalized medicine and the clinical laboratory. Einstein (Sao Paulo, Brazil), 2014, 12, 366-373.	0.7	8
151	Exploring Rates of Abnormal Pharmacogenetic Findings in a Pain Practice. Journal of Pain and Palliative Care Pharmacotherapy, 2014, 28, 28-32.	0.8	3

#	ARTICLE	IF	CITATIONS
152	“Doctor shopping and pharmacy hopping”: practice innovations relating to codeine. <i>Drugs and Alcohol Today</i> , 2014, 14, 219-234.	0.7	14
153	Resolution of a clinical AmpliChip CYP450 Test [®] no call: discovery and characterization of novel CYP2D6*1 haplotypes. <i>Pharmacogenomics</i> , 2014, 15, 1175-1184.	1.3	11
154	Priority pharmacogenetics for the African continent: focus on CYP450. <i>Pharmacogenomics</i> , 2014, 15, 385-400.	1.3	10
155	PBPK Model Describes the Effects of Comedication and Genetic Polymorphism on Systemic Exposure of Drugs That Undergo Multiple Clearance Pathways. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 550-557.	4.7	56
156	Precursors for cytochrome P450 profiling breath tests from an in silico screening approach. <i>Journal of Breath Research</i> , 2014, 8, 046001.	3.0	1
157	Stereoselective analysis of flecainide enantiomers using reversed-phase liquid chromatography for assessing CYP2D6 activity. <i>Biomedical Chromatography</i> , 2014, 28, 1193-1198.	1.7	4
158	The Effect of CYP2D6 Drug-Drug Interactions on Hydrocodone Effectiveness. <i>Academic Emergency Medicine</i> , 2014, 21, 879-885.	1.8	45
159	G Protein-Coupled Receptor Kinase 5 Gene Polymorphisms Are Associated With Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting in Patients Receiving β -Blockers. <i>Circulation: Cardiovascular Genetics</i> , 2014, 7, 625-633.	5.1	24
160	PharmGKB summary. <i>Pharmacogenetics and Genomics</i> , 2014, 24, 374-380.	1.5	80
161	Genomic architecture of pharmacological efficacy and adverse events. <i>Pharmacogenomics</i> , 2014, 15, 2025-2048.	1.3	21
162	Characterization of a complex CYP2D6 genotype that caused an AmpliChip CYP450 Test [®] no-call in the clinical setting. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, 799-807.	2.3	15
163	Serum Concentrations of Risperidone and Aripiprazole in Subgroups Encoding CYP2D6 Intermediate Metabolizer Phenotype. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 80-85.	2.0	26
164	Late positive flecainide challenge test for Brugada syndrome. <i>Heart Rhythm</i> , 2014, 11, 898-900.	0.7	5
165	Preoperative CYP2D6 metabolism-dependent β -blocker use and mortality after coronary artery bypass grafting surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 147, 1368-1375.e3.	0.8	12
166	Polymorphism of CYP1A1 gene and susceptibility to childhood acute lymphoblastic leukemia in Egypt. <i>Leukemia and Lymphoma</i> , 2014, 55, 618-623.	1.3	5
167	Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: implications for the 8-aminoquinoline class of anti-malarial compounds. <i>Malaria Journal</i> , 2014, 13, 2.	2.3	73
168	The influence of comedication on tacrolimus blood concentration in patients subjected to kidney transplantation: a retrospective study. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2014, 39, 243-253.	1.6	12
169	Observations on the Urine Metabolic Profile of Codeine in Pain Patients. <i>Journal of Analytical Toxicology</i> , 2014, 38, 86-91.	2.8	19

#	ARTICLE	IF	CITATIONS
170	Antiplatelet drug interactions with proton pump inhibitors. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 175-189.	3.3	35
171	<i>CYP2D6</i> and pharmacogenomics: where does future research need to focus? Part 2: clinical aspects. Pharmacogenomics, 2014, 15, 1055-1058.	1.3	7
172	Prediction of interindividual differences in hepatic functions and drug sensitivity by using human iPSC-derived hepatocytes. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 16772-16777.	7.1	171
173	Population pharmacokinetic modelling of tramadol using inverse Gaussian function for the assessment of drug absorption from prolonged and immediate release formulations. International Journal of Pharmaceutics, 2014, 473, 170-178.	5.2	12
174	Population pharmacokinetic approach to evaluate the effect of <i>CYP2D6</i>, <i>CYP3A</i>, <i>ABCB1</i>, <i>POR</i> and <i>NR112</i> genotypes on donepezil clearance. British Journal of Clinical Pharmacology, 2014, 78, 135-144.	2.4	46
175	<i>CYP2D6</i> and pharmacogenomics: where does future research need to focus? Part 1: technical aspects. Pharmacogenomics, 2014, 15, 407-410.	1.3	9
176	Personalized Oxycodone Dosing: Using Pharmacogenetic Testing and Clinical Pharmacokinetics to Reduce Toxicity Risk and Increase Effectiveness. Pain Medicine, 2014, 15, 791-806.	1.9	34
177	Variation in the <i>CYP2D6</i> genotype is not associated with carvedilol dose changes in patients with heart failure. Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 432-438.	1.5	12
178	Establishment of CYP2D6 reference samples by multiple validated genotyping platforms. Pharmacogenomics Journal, 2014, 14, 564-572.	2.0	27
179	Pharmacogenomic Testing for Neuropsychiatric Drugs: Current Status of Drug Labeling, Guidelines for Using Genetic Information, and Test Options. Pharmacotherapy, 2014, 34, 166-184.	2.6	69
180	Evaluation of the Pharmacokinetic Interaction Between Ticagrelor and Venlafaxine, a Cytochrome P-450 2D6 Substrate, in Healthy Subjects. Clinical Therapeutics, 2014, 36, 1217-1225.	2.5	7
181	The relationship between plasma concentration of metoprolol and CYP2D6 genotype in patients with ischemic heart disease. Pharmacological Reports, 2014, 66, 511-514.	3.3	5
182	Effect of Preoperative Acetaminophen/Hydrocodone on the Efficacy of the Inferior Alveolar Nerve Block in Patients with Symptomatic Irreversible Pulpitis: A Prospective, Randomized, Double-blind, Placebo-controlled Study. Journal of Endodontics, 2014, 40, 1-5.	3.1	27
183	Is there more to learn about cytochrome P450 enzymes?: Table.. Drug and Therapeutics Bulletin, 2014, 52, 57-60.	0.3	0
184	Review of therapeutic drug monitoring of anticancer drugs part two – Targeted therapies. European Journal of Cancer, 2014, 50, 2020-2036.	2.8	248
185	Anesthetic pharmacology: Physiologic states, pathophysiologic states, and adverse effects. , 0, , 27-37.		0
187	Stereoselective metabolism of donepezil and steady-state plasma concentrations of S-donepezil based on CYP2D6 polymorphisms in the therapeutic responses of Han Chinese patients with Alzheimer's disease. Journal of Pharmacological Sciences, 2015, 129, 188-195.	2.5	19
188	Prolonged neuropsychiatric effects following management of chloroquine intoxication with psychotropic polypharmacy. Clinical Case Reports (discontinued), 2015, 3, 379-387.	0.5	30

#	ARTICLE	IF	CITATIONS
189	Serotonin syndrome: a spectrum of toxicity. <i>BJ Psych Advances</i> , 2015, 21, 324-332.	0.7	11
190	Evaluation of the likelihood of a selective CHK1 inhibitor (LY2603618) to inhibit CYP2D6 with desipramine as a probe substrate in cancer patients. <i>Biopharmaceutics and Drug Disposition</i> , 2015, 36, 49-63.	1.9	5
191	Pharmacogenomics and Implications for Nursing Practice. <i>Journal of Nursing Scholarship</i> , 2015, 47, 496-504.	2.4	19
192	The Anti-Addiction Drug Ibogaine and the Heart: A Delicate Relation. <i>Molecules</i> , 2015, 20, 2208-2228.	3.8	69
193	Prevalence of the CYP2D6*10 (C100T), *4 (G1846A), and *14 (G1758A) alleles among Iranians of different ethnicities. <i>Drug Design, Development and Therapy</i> , 2015, 9, 2627.	4.3	20
194	CYP2D6*4 polymorphism: A new marker of response to hormonotherapy in male breast cancer?. <i>Breast</i> , 2015, 24, 481-486.	2.2	10
195	Pharmacogenetics of drug-metabolizing enzymes in Italian populations. <i>Drug Metabolism and Personalized Therapy</i> , 2015, 30, 107-120.	0.6	14
196	Â»Treatment ResistanceÂ« Enigma Resolved by Pharmacogenomics âˆ’ A Case Study of Clozapine Therapy in Schizophrenia / Enigma Â»Terapo-RezistenceÂ« RazreÅ¡ena Uz PomoÅ† Farmakogenomike - Prikaz SluÅ†aja Terapije Klopazinom U Shizofreniji. <i>Journal of Medical Biochemistry</i> , 2015, 34, 223-227.	1.7	7
197	Impact of physiological, pathological and environmental factors on the expression and activity of human cytochrome P450 2D6 and implications in precision medicine. <i>Drug Metabolism Reviews</i> , 2015, 47, 470-519.	3.6	58
198	Pharmacogenomics and cardiology: improving treatment with existing drugs. <i>Pharmacogenomics</i> , 2015, 16, 1223-1226.	1.3	1
199	Evaluation of the impact of cantharidin on rat CYP enzymes by using a cocktail of probe drugs. <i>FÅ-toterapÅ-Å†</i> , 2015, 107, 49-53.	2.2	11
200	Effects of 24 CYP2D6 Variants Found in the Chinese Population on the Metabolism of Risperidone. <i>Pharmacology</i> , 2015, 96, 290-295.	2.2	8
201	Over-the-Counter Codeineâ€”from Therapeutic Use to Dependence, and the Grey Areas in Between. <i>Current Topics in Behavioral Neurosciences</i> , 2015, 34, 59-75.	1.7	27
202	Codeine and breast-feeding mothers. <i>International Journal of Obstetric Anesthesia</i> , 2015, 24, 5-7.	0.4	3
203	The role of quantitative ADME proteomics to support construction of physiologically based pharmacokinetic models for use in small molecule drug development. <i>Proteomics - Clinical Applications</i> , 2015, 9, 732-744.	1.6	27
204	CYP2D6, CYP3A5, and CYP3A4 gene polymorphisms in Russian, Tatar, and Bashkir populations. <i>Russian Journal of Genetics</i> , 2015, 51, 98-107.	0.6	14
205	Differential CYP 2D6 Metabolism Alters Primaquine Pharmacokinetics. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2380-2387.	3.2	66
206	Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes. <i>Pharmacogenomics Journal</i> , 2015, 15, 443-451.	2.0	91

#	ARTICLE	IF	CITATIONS
207	Drug Management in the Elderly Adult With Chronic Kidney Disease: A Review for the Primary Care Physician. Mayo Clinic Proceedings, 2015, 90, 633-645.	3.0	40
208	Characterization of the CYP2D6 drug metabolizing phenotypes of the Chilean mestizo population through polymorphism analyses. Pharmacological Research, 2015, 101, 124-129.	7.1	21
209	Cypiripi: exact genotyping of <i>CYP2D6</i> using high-throughput sequencing data. Bioinformatics, 2015, 31, i27-i34.	4.1	37
210	SNP genotyping using TaqMan® technology: the CYP2D6*17 assay conundrum. Scientific Reports, 2015, 5, 9257.	3.3	24
211	Electrochemistry of Canis familiaris cytochrome P450 2D15 with gold nanoparticles: An alternative to animal testing in drug discovery. Bioelectrochemistry, 2015, 105, 110-116.	4.6	9
212	Pharmacogenetics Informed Decision Making in Adolescent Psychiatric Treatment: A Clinical Case Report. International Journal of Molecular Sciences, 2015, 16, 4416-4428.	4.1	20
213	The Pharmacogenetics of Tramadol. Clinical Pharmacokinetics, 2015, 54, 825-836.	3.5	66
214	Repression of multiple CYP2D genes in mouse primary hepatocytes with a single siRNA construct. In Vitro Cellular and Developmental Biology - Animal, 2015, 51, 9-14.	1.5	3
215	Associations between <i>ADRB1</i> and <i>CYP2D6</i> gene polymorphisms and the response to ß-blocker therapy in hypertension. Journal of International Medical Research, 2015, 43, 424-434.	1.0	33
216	Opioid Analgesics and Nicotine: More Than Blowing Smoke. Journal of Pain and Palliative Care Pharmacotherapy, 2015, 29, 281-289.	0.8	39
218	Serum flecainide S/R ratio reflects the CYP2D6 genotype and changes in CYP2D6 activity. Drug Metabolism and Pharmacokinetics, 2015, 30, 257-262.	2.2	11
219	CYP2D6 Haplotype Determination Using Long Range Allele-Specific Amplification. Journal of Molecular Diagnostics, 2015, 17, 740-748.	2.8	38
220	Clinical applications of CYP genotyping in psychiatry. Journal of Neural Transmission, 2015, 122, 5-28.	2.8	122
221	<i>In Vitro</i> Functional Assessment of 22 Newly Identified CYP2D6 Allelic Variants in the Chinese Population. Basic and Clinical Pharmacology and Toxicology, 2015, 117, 39-43.	2.5	24
222	Physiology-Based IVIVE Predictions of Tramadol from in Vitro Metabolism Data. Pharmaceutical Research, 2015, 32, 260-274.	3.5	19
223	Chemical inhibitors of CYP450 enzymes in liver microsomes: combining selectivity and unbound fractions to guide selection of appropriate concentration in phenotyping assays. Xenobiotica, 2015, 45, 95-106.	1.1	27
224	Nod and wave: An Internet study of the codeine intoxication phenomenon. International Journal of Drug Policy, 2015, 26, 67-77.	3.3	38
225	Pain and side effects in older people. NursePrescribing, 2016, 14, 44-49.	0.1	0

#	ARTICLE	IF	CITATIONS
226	Potential utility of precision medicine for older adults with polypharmacy: a case series study. <i>Pharmacogenomics and Personalized Medicine</i> , 2016, 9, 31.	0.7	29
227	Role of Genetic Polymorphism of Cyp2d6 in Tramadol Related Nephrotoxicity. <i>Journal of Medical Toxicology and Clinical Forensic Medicine</i> , 2016, 2, .	0.2	0
228	Role of cytochrome P450 2D6 genetic polymorphism in carvedilol hydroxylation in vitro. <i>Drug Design, Development and Therapy</i> , 2016, 10, 1909.	4.3	9
229	CYP2D6 polymorphisms and their influence on risperidone treatment. <i>Pharmacogenomics and Personalized Medicine</i> , 2016, Volume 9, 131-147.	0.7	26
230	Factors affecting the development of adverse drug reactions to β -blockers in hospitalized cardiac patient population. <i>Patient Preference and Adherence</i> , 2016, Volume 10, 1461-1469.	1.8	9
231	Genetic polymorphisms analysis of CYP2D6 in the Uyghur population. <i>BMC Genomics</i> , 2016, 17, 409.	2.8	12
232	Impact of Cytochrome P450 2D6 Function on the Chiral Blood Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine (MDMA) and Its Phase I and II Metabolites in Humans. <i>PLoS ONE</i> , 2016, 11, e0150955.	2.5	7
233	CYP2D7 Sequence Variation Interferes with TaqMan CYP2D6*15 and *35 Genotyping. <i>Frontiers in Pharmacology</i> , 2015, 6, 312.	3.5	13
234	The role of cytochrome P450 pharmacogenomics in chronic non-cancer pain patients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1303-1311.	3.3	4
235	Ultrarapid clozapine metabolism and CYP2D6 gene duplication in a patient with schizophrenia. <i>Personalized Medicine</i> , 2016, 13, 113-117.	1.5	3
236	Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 266-283.	2.0	104
237	CYP2D6 copy number distribution in the US population. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 96-99.	1.5	46
238	Impact of Ageing on Serum Concentrations of Risperidone and Its Active Metabolite in Patients with Known CYP2D6 Genotype. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2016, 119, 470-475.	2.5	11
239	Pharmacogenomics of preterm birth prevention and treatment. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2016, 123, 368-375.	2.3	18
240	Effects of 22 Novel CYP2D6 Variants Found in the Chinese Population on the Bufuralol and Dextromethorphan Metabolisms <i>In Vitro</i> . <i>Basic and Clinical Pharmacology and Toxicology</i> , 2016, 118, 190-199.	2.5	20
241	Clinical Response to Donepezil in Mild and Moderate Dementia: Relationship to Drug Plasma Concentration and CYP2D6 and APOE Genetic Polymorphisms. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 539-549.	2.6	20
242	Effects of the Chinese herbal formula "Zuojin Pill" on the pharmacokinetics of dextromethorphan in healthy Chinese volunteers with CYP2D6*10 genotype. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 689-695.	1.9	12
243	Constellation: a tool for rapid, automated phenotype assignment of a highly polymorphic pharmacogene, CYP2D6, from whole-genome sequences. <i>Npj Genomic Medicine</i> , 2016, 1, 15007.	3.8	93

#	ARTICLE	IF	CITATIONS
244	CYP2D6 variability in populations from Venezuela. Drug Metabolism and Personalized Therapy, 2016, 31, 181-189.	0.6	4
245	Effect of Evodiamine on CYP Enzymes in Rats by a Cocktail Method. Pharmacology, 2016, 97, 218-223.	2.2	12
246	Pre-clinical evaluation of CYP 2D6 dependent drug-drug interactions between primaquine and SSRI/SNRI antidepressants. Malaria Journal, 2016, 15, 280.	2.3	14
247	Clinical research in neonates and infants: Challenges and perspectives. Pharmacological Research, 2016, 108, 80-87.	7.1	45
248	Gene signatures of postoperative atrial fibrillation in atrial tissue after coronary artery bypass grafting surgery in patients receiving β -blockers. Journal of Molecular and Cellular Cardiology, 2016, 92, 109-115.	1.9	12
249	Assessment of 25 CYP2D6 alleles found in the Chinese population on propafenone metabolism in vitro. Canadian Journal of Physiology and Pharmacology, 2016, 94, 895-899.	1.4	2
250	Primaquine treatment and relapse in Plasmodium vivax malaria. Pathogens and Global Health, 2016, 110, 1-8.	2.3	19
251	Effect of 24 cytochrome P450 2D6 variants found in the Chinese population on the N-demethylation of amitriptyline in vitro. Pharmaceutical Biology, 2016, 54, 2475-2479.	2.9	0
252	Confining nanohybrid of CdTe quantum dots and cytochrome P450 2D6 in macroporous ordered siliceous foam for drug metabolism. Journal of Electroanalytical Chemistry, 2016, 781, 345-350.	3.8	7
253	Response to Keszthelyi et al.. American Journal of Gastroenterology, 2016, 111, 1036-1037.	0.4	0
254	Pharmacogenetics to prevent maniac affective switching with treatment for bipolar disorder: CYP2D6. Pharmacogenomics, 2016, 17, 1291-1293.	1.3	4
255	Application of a physiologically based pharmacokinetic model for the evaluation of single-point plasma phenotyping method of CYP2D6. European Journal of Pharmaceutical Sciences, 2016, 92, 131-136.	4.0	5
257	Comparative metabolism of tramadol and tapentadol: a toxicological perspective. Drug Metabolism Reviews, 2016, 48, 577-592.	3.6	55
258	Cardiac safety of ophthalmic timolol. Expert Opinion on Drug Safety, 2016, 15, 1549-1561.	2.4	42
259	Perioperative management in children with chronic pain. Paediatric Anaesthesia, 2016, 26, 794-806.	1.1	84
260	Challenges of development and implementation of point of care pharmacogenetic testing. Expert Review of Molecular Diagnostics, 2016, 16, 949-960.	3.1	27
261	Pharmacogenomics of heart failure: a systematic review. Pharmacogenomics, 2016, 17, 1817-1858.	1.3	10
262	Loss-of-function polymorphisms in the organic cation transporter OCT1 are associated with reduced postoperative tramadol consumption. Pain, 2016, 157, 2467-2475.	4.2	45

#	ARTICLE	IF	CITATIONS
263	Genetic Variants of Cytochrome <i>CYP2D6</i> in Two Mixed Chilean Populations. Human Heredity, 2016, 82, 16-20.	0.8	1
264	Functional characterization of 22 novel <i>CYP2D6</i> variants for the metabolism of Tamoxifen. Journal of Pharmacy and Pharmacology, 2016, 68, 819-825.	2.4	6
265	Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that <i>CYP2D6</i> reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial. Malaria Journal, 2016, 15, 97.	2.3	75
266	Evaluation of Adherence Should Become an Integral Part of Assessment of Patients With Apparently Treatment-Resistant Hypertension. Hypertension, 2016, 68, 297-306.	2.7	147
267	Competitive Sports Participation in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia. JACC: Clinical Electrophysiology, 2016, 2, 253-262.	3.2	45
268	Multiplex SNaPshot™ a new simple and efficient <i>CYP2D6</i> and <i>ADRB1</i> genotyping method. Human Genomics, 2016, 10, 11.	2.9	7
269	Pharmacokinetics of metoprolol during pregnancy and lactation. Journal of Clinical Pharmacology, 2016, 56, 581-589.	2.0	52
270	<i>CYP450</i> genotype and pharmacogenetic association studies: a critical appraisal. Pharmacogenomics, 2016, 17, 259-275.	1.3	38
271	Bringing clinical pharmacogenomics information to pharmacists: A qualitative study of information needs and resource requirements. International Journal of Medical Informatics, 2016, 86, 54-61.	3.3	27
272	A Physiologic Approach to the Pharmacogenomics of Hypertension. Advances in Chronic Kidney Disease, 2016, 23, 91-105.	1.4	9
273	Treating codeine dependence with buprenorphine: Dose requirements and induction outcomes from a retrospective case series in New South Wales, Australia. Drug and Alcohol Review, 2016, 35, 70-75.	2.1	7
274	Tramadol Abuse and Sexual Function. Sexual Medicine Reviews, 2016, 4, 235-246.	2.9	39
275	Detection of <i>CYP2D6</i> polymorphism using Luminex xTAG technology in autism spectrum disorder: <i>CYP2D6</i> activity score and its association with risperidone levels. Drug Metabolism and Pharmacokinetics, 2016, 31, 156-162.	2.2	31
276	Effect of <i>CYP2D6</i> genetic polymorphism on the metabolism of citalopram in vitro. Drug Metabolism and Pharmacokinetics, 2016, 31, 133-138.	2.2	9
277	Impact of a personal <i>CYP2D6</i> testing workshop on physician assistant student attitudes toward pharmacogenetics. Pharmacogenomics, 2016, 17, 341-352.	1.3	15
278	Role of Pharmacogenetics in Improving the Safety of Psychiatric Care by Predicting the Potential Risks of Mania in <i>CYP2D6</i> Poor Metabolizers Diagnosed With Bipolar Disorder. Medicine (United States), 2016, 95, e2473.	1.0	18
279	Influence of <i>CYP2B6</i> and <i>CYP2C19</i> polymorphisms on sertraline metabolism in major depression patients. International Journal of Clinical Pharmacy, 2016, 38, 388-394.	2.1	26
281	Functional characterization of <i>CYP2D6</i> novel allelic variants identified in the Chinese Han population. Pharmacogenomics, 2016, 17, 119-9.	1.3	4

#	ARTICLE	IF	CITATIONS
282	Effect of 24 Cytochrome P450 2D6 Variants Found in the Chinese Population on Atomoxetine Metabolism in vitro. Pharmacology, 2016, 97, 78-83.	2.2	7
283	Effect of 22 Novel Cytochrome P450 2D6 (CYP2D6) Variants Found in the Chinese Population on Hemangeol Metabolism In Vitro. European Journal of Drug Metabolism and Pharmacokinetics, 2016, 41, 759-765.	1.6	6
284	Species differences in metabolism of EPZ015666, an oxetane-containing protein arginine methyltransferase-5 (PRMT5) inhibitor. Xenobiotica, 2016, 46, 268-277.	1.1	14
285	Impact of New Genomic Technologies on Understanding Adverse Drug Reactions. Clinical Pharmacokinetics, 2016, 55, 419-436.	3.5	13
286	Development of HepG2-derived cells expressing cytochrome P450s for assessing metabolism-associated drug-induced liver toxicity. Chemico-Biological Interactions, 2016, 255, 63-73.	4.0	62
287	Pharmacogenetic comparison of CYP2D6 predictive and measured phenotypes in a South African cohort. Pharmacogenomics Journal, 2016, 16, 566-572.	2.0	10
288	Effect of CYP2D6 variants on venlafaxine metabolism in vitro. Xenobiotica, 2016, 46, 424-429.	1.1	13
289	Impact of CYP2D6 Polymorphism on Steady-State Plasma Levels of Risperidone and 9-Hydroxyrisperidone in Thai Children and Adolescents with Autism Spectrum Disorder. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 185-191.	1.3	28
290	Prediction of CYP2D6 phenotype from genotype across world populations. Genetics in Medicine, 2017, 19, 69-76.	2.4	365
291	Downregulation of the β_1 adrenergic receptor in the myocardium results in insensitivity to metoprolol and reduces blood pressure in spontaneously hypertensive rats. Molecular Medicine Reports, 2017, 15, 703-711.	2.4	9
292	Effect of CYP2D6 polymorphisms on the pharmacokinetics of propafenone and its two main metabolites. Therapie, 2017, 72, 373-382.	1.0	8
293	Effect of 22 CYP2D6 variants found in the Chinese population on tolterodine metabolism in vitro. Chemico-Biological Interactions, 2017, 264, 10-15.	4.0	0
294	Pharmacogenomics of Neurodegenerative Diseases: Roles in Personalized Medicines. , 2017, , 959-970.		0
295	Genotyping CYP2D6 by three different methods: advantages and disadvantages. Drug Metabolism and Personalized Therapy, 2017, 32, 33-37.	0.6	1
296	Revisiting Boronate/Diol Complexation as a Double Stimulus-Responsive Bioconjugation. Bioconjugate Chemistry, 2017, 28, 1391-1402.	3.6	36
297	CYP2D6 pharmacogenomics. Egyptian Journal of Medical Human Genetics, 2017, 18, 309-313.	1.0	27
298	Design, synthesis, biological evaluation and molecular modelling of 2-(2-aryloxyphenyl)-1,4-dihydroisoquinolin-3(2 H)-ones: A novel class of TSPO ligands modulating amyloid- β -induced mPTP opening. European Journal of Pharmaceutical Sciences, 2017, 104, 366-381.	4.0	23
299	Cytochrome P450-mediated metabolism of triclosan attenuates its cytotoxicity in hepatic cells. Archives of Toxicology, 2017, 91, 2405-2423.	4.2	37

#	ARTICLE	IF	CITATIONS
300	Beta-blocker use and fall risk in older individuals: Original results from two studies with meta-analysis. British Journal of Clinical Pharmacology, 2017, 83, 2292-2302.	2.4	27
301	In vitro metabolism of exemestane by hepatic cytochrome P450s: impact of nonsynonymous polymorphisms on formation of the active metabolite 17 β -dihydroexemestane. Pharmacology Research and Perspectives, 2017, 5, e00314.	2.4	13
302	Clinical and educational impact of pharmacogenomics testing: a case series from the INGENIOUS trial. Pharmacogenomics, 2017, 18, 835-841.	1.3	6
303	Allele Drop Out Conferred by a Frequent CYP2D6 Genetic Variation For Commonly Used CYP2D6*3 Genotyping Assays. Cellular Physiology and Biochemistry, 2017, 43, 2297-2309.	1.6	14
304	Genetic Polymorphisms of Cytochrome P450 Enzymes and Transport Proteins in a Russian Population and Three Ethnic Groups of Dagestan. Genetic Testing and Molecular Biomarkers, 2017, 21, 747-753.	0.7	14
305	Review of Opioid Pharmacogenetics and Considerations for Pain Management. Pharmacotherapy, 2017, 37, 1105-1121.	2.6	113
306	The effect of rs5758550 on CYP2D6*2 phenotype and formation of endoxifen in breast cancer patients using tamoxifen. Pharmacogenomics, 2017, 18, 1125-1132.	1.3	19
307	Evaluation of CYP2D6 phenotype in the Yoruba Nigerian population. Expert Review of Clinical Pharmacology, 2017, 10, 1145-1152.	3.1	3
308	Impact of CYP2D6 and ADRB1 polymorphisms on heart rate of post-PCI patients treated with metoprolol. Pharmacogenomics, 2017, , .	1.3	9
309	The role of tramadol in pain management in Latin America: a report by the Change Pain Latin America Advisory Panel. Current Medical Research and Opinion, 2017, 33, 1615-1621.	1.9	9
310	The Influence of CYP2D6 Phenotype on the Pharmacokinetic Profile of Atomoxetine in Caucasian Healthy Subjects. Acta Marisiensis - Seria Medica, 2017, 63, 73-79.	0.3	1
311	Validation of an Extensive CYP2D6 Assay Panel Based on Invader and TaqMan Copy Number Assays. journal of applied laboratory medicine, The, 2017, 1, 471-482.	1.3	10
312	Tramadol Intoxication in an 8-Months-Old Infant through Breastfeeding: A Case Report. Journal of Clinical & Experimental Dermatology Research, 2017, 07, .	0.1	1
313	Revisiting propafenone toxicity. BMJ Case Reports, 2017, 2017, bcr-2017-219270.	0.5	11
314	Functional characterization of wild-type and 24 CYP2D6 allelic variants on gefitinib metabolism in vitro. Drug Design, Development and Therapy, 2017, Volume 11, 1283-1290.	4.3	12
315	CYP2D6 Phenotyping Using Urine, Plasma, and Saliva Metabolic Ratios to Assess the Impact of CYP2D6*10 on Interindividual Variation in a Chinese Population. Frontiers in Pharmacology, 2017, 8, 239.	3.5	12
316	Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen. Frontiers in Pharmacology, 2017, 8, 582.	3.5	52
317	Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children. Journal of Personalized Medicine, 2017, 7, 14.	2.5	29

#	ARTICLE	IF	CITATIONS
319	Guidelines for Therapeutic Drug Monitoring of Cardiovascular Drugs Clinical Use of Blood Drug Concentration Monitoring (JCS 2015)â€• Digest Version â€•. Circulation Journal, 2017, 81, 581-612.	1.6	33
320	Pain in labour and the intrapartum use of intramuscular opioidsâ€”how effective are they?. British Journal of Midwifery, 2017, 25, 418-424.	0.4	7
321	Precision Medicine and Challenges in Research and Clinical Implementation. , 2017, , 717-732.		3
322	Selective inhibition of CYP2C8 by fisetin and its methylated metabolite, geraldol, in human liver microsomes. Drug Metabolism and Pharmacokinetics, 2018, 33, 111-117.	2.2	12
323	Development of a linear dual column HPLCâ€”MS/MS method and clinical genetic evaluation for tramadol and its phase I and II metabolites in oral fluid. Archives of Pharmacal Research, 2018, 41, 288-298.	6.3	11
324	Genetic polymorphisms in amyotrophic lateral sclerosis: Evidence for implication in detoxification pathways of environmental toxicants. Environment International, 2018, 116, 122-135.	10.0	42
325	Is CYP2D6 phenotype predictable from CYP2D6 genotype?. Microchemical Journal, 2018, 136, 209-214.	4.5	8
326	Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry, 2018, 51, 9-62.	3.3	787
327	Transcriptomic, Proteomic, and Functional Long-Term Characterization of Multicellular Three-Dimensional Human Liver Microtissues. Applied in Vitro Toxicology, 2018, 4, 1-12.	1.1	46
328	â€”Codeine is my companionâ€™: misuse and dependence on codeine containing medicines in Ireland. Irish Journal of Psychological Medicine, 2018, 35, 275-288.	1.0	30
329	Efficient Generation of Small Intestinal Epithelial-like Cells from Human iPSCs for Drug Absorption and Metabolism Studies. Stem Cell Reports, 2018, 11, 1539-1550.	4.8	45
330	Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent<i>Plasmodium vivax</i> Malaria. JAMA Network Open, 2018, 1, e181449.	5.9	77
331	Genetic Polymorphisms and In Silico Mutagenesis Analyses of CYP2C9, CYP2D6, and CYPOR Genes in the Pakistani Population. Genes, 2018, 9, 514.	2.4	4
332	lbogaine as a treatment for substance misuse: Potential benefits and practical dangers. Progress in Brain Research, 2018, 242, 217-257.	1.4	37
333	Association between cytochrome P450 2D6 polymorphisms and body fluid methamphetamine concentrations in Japanese forensic autopsy cases. Forensic Science International, 2018, 289, 33-39.	2.2	3
334	Relapsing Malaria: A Case Report of Primaquine Resistance. Case Reports in Infectious Diseases, 2018, 2018, 1-3.	0.5	8
335	Interaction between CYP2D6 inhibitor antidepressants and codeine: is this relevant?. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 879-886.	3.3	12
336	When the Safe Alternative Is Not That Safe: Tramadol Prescribing in Children. Frontiers in Pharmacology, 2018, 9, 148.	3.5	34

#	ARTICLE	IF	CITATIONS
337	Malaria Elimination in the Greater Mekong Subregion: Challenges and Prospects. , 0, , .		12
338	A systematic review of the effects of CYP2D6 phenotypes on risperidone treatment in children and adolescents. Child and Adolescent Psychiatry and Mental Health, 2018, 12, 37.	2.5	17
339	Outâ€compute drug side effects: Focus on cytochrome P450 2D6 modeling. Wiley Interdisciplinary Reviews: Computational Molecular Science, 2018, 8, e1366.	14.6	9
340	Effect of Naltrexone Hydrochloride on Cytochrome P450 1A2, 2C9, 2D6, and 3A4 Activity in Human Liver Microsomes. European Journal of Drug Metabolism and Pharmacokinetics, 2018, 43, 707-713.	1.6	9
341	Molecular Dynamics Simulations Reveal Structural Differences among Allelic Variants of Membrane-Anchored Cytochrome P450 2D6. Journal of Chemical Information and Modeling, 2018, 58, 1962-1975.	5.4	21
342	CYP2D6 Allelic Variants *34, *17-2, *17-3, and *53 and a Thr309Ala Mutant Display Altered Kinetics and NADPH Coupling in Metabolism of Bufuralol and Dextromethorphan and Altered Susceptibility to Inactivation by SCH 66712. Drug Metabolism and Disposition, 2018, 46, 1106-1117.	3.3	4
343	Pharmacogenetics. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 147, 59-73.	1.8	16
344	<scp>CYP</scp>2D6 Genotype Phenotype Discordance Due to Drugâ€Drug Interaction. Clinical Pharmacology and Therapeutics, 2018, 104, 933-939.	4.7	10
345	Stargazer: a software tool for calling star alleles from next-generation sequencing data using CYP2D6 as a model. Genetics in Medicine, 2019, 21, 361-372.	2.4	86
346	Perioperative Î²-Adrenergic Blockade in Noncardiac and Cardiac Surgery: A Clinical Update. Journal of Cardiothoracic and Vascular Anesthesia, 2019, 33, 817-832.	1.3	9
347	<i>CYP2D6</i> Polymorphisms and the Safety and Gametocytocidal Activity of Single-Dose Primaquine for Plasmodium falciparum. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	13
348	Multiple relapses of Plasmodium vivax malaria acquired from West Africa and association with poor metabolizer CYP2D6 variant: a case report. BMC Infectious Diseases, 2019, 19, 704.	2.9	20
349	Characterization of Reference Materials for Genetic Testing of CYP2D6 Alleles. Journal of Molecular Diagnostics, 2019, 21, 1034-1052.	2.8	55
350	Challenges to assess substrate-dependent allelic effects in CYP450 enzymes and the potential clinical implications. Pharmacogenomics Journal, 2019, 19, 501-515.	2.0	16
351	Metabolism of Benzalkonium Chlorides by Human Hepatic Cytochromes P450. Chemical Research in Toxicology, 2019, 32, 2466-2478.	3.3	26
352	Quantification of microdosed oral yohimbine and its major metabolite in human plasma in the picogram range. Bioanalysis, 2019, 11, 1459-1467.	1.5	12
353	Dopamine Receptor Partial Agonists for the Treatment of Bipolar Disorder. Drugs, 2019, 79, 1657-1677.	10.9	12
354	<p>Influence of CYP2D6, CYP3A5, ABCB1, APOE polymorphisms and nongenetic factors on donepezil treatment in patients with Alzheimerâ€™s disease and vascular dementia</p>. Pharmacogenomics and Personalized Medicine, 2019, Volume 12, 209-224.	0.7	11

#	ARTICLE	IF	CITATIONS
355	Determination of Cytochrome P450 Isoenzyme 2D6 (CYP2D6) Genotypes and Pharmacogenomic Impact on Primaquine Metabolism in an Active-Duty US Military Population. <i>Journal of Infectious Diseases</i> , 2019, 220, 1761-1770.	4.0	26
356	CYP2D6 Genotype Predicts Plasma Concentrations of Tamoxifen Metabolites in Ethiopian Breast Cancer Patients. <i>Cancers</i> , 2019, 11, 1353.	3.7	14
357	Effects of 24 CYP2D6 variants found in Chinese population on the metabolism of clonidine in vitro. <i>Chemico-Biological Interactions</i> , 2019, 313, 108840.	4.0	5
358	Polymorphisms of CYP2C8 Alter First-Electron Transfer Kinetics and Increase Catalytic Uncoupling. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4626.	4.1	5
359	Analysis of Lithuanian CYP2D6 polymorphism and its relevance to psychiatric care of the local population. <i>Nordic Journal of Psychiatry</i> , 2019, 73, 31-35.	1.3	3
360	Human iPS Cell-Derived Patient Tissues and 3D Cell Culture Part 1: Target Identification and Lead Optimization. <i>SLAS Technology</i> , 2019, 24, 3-17.	1.9	9
361	Absence of herb-drug interactions of mistletoe with the tamoxifen metabolite (E/Z)-endoxifen and cytochrome P450 3A4/5 and 2D6 in vitro. <i>BMC Complementary and Alternative Medicine</i> , 2019, 19, 23.	3.7	14
362	Calling Star Alleles With Stargazer in 28 Pharmacogenes With Whole Genome Sequences. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1328-1337.	4.7	57
363	Comparative research on the metabolism of metoprolol by four CYP2D6 allelic variants in vitro with LC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 174, 479-485.	2.8	4
364	CYP2D6 metabolizer status and HTTLPR variant of SLC6A4 associated with antidepressant-induced mania in bipolar disorder. <i>Personalized Medicine in Psychiatry</i> , 2019, 13-14, 6-10.	0.1	0
365	The Advantages and Challenges of Diversity in Pharmacogenomics: Can Minority Populations Bring Us Closer to Implementation?. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 338-349.	4.7	31
366	Rolapitant Is a Reversible Inhibitor of CYP2D6. <i>Drug Metabolism and Disposition</i> , 2019, 47, 567-573.	3.3	4
367	<p>Clinical utility of tafenoquine in the prevention of relapse of Plasmodium vivax; malaria: a review on the mode of action and emerging trial data</p>. <i>Infection and Drug Resistance</i> , 2019, Volume 12, 553-570.	2.7	40
368	Determinants of Cytochrome P450 2D6 <sc>mRNA</sc> Levels in Healthy Human Liver Tissue. <i>Clinical and Translational Science</i> , 2019, 12, 416-423.	3.1	5
369	Postmortem CYP2D6 Genotyping and Copy Number Determinations Using DNA Extracted from Archived FTA Bloodstains. <i>Journal of Analytical Toxicology</i> , 2019, 43, 411-414.	2.8	3
370	Cytochrome P450 enzymes contribute to the metabolism of LSD to nor-LSD and 2-oxo-3-hydroxy-LSD: Implications for clinical LSD use. <i>Biochemical Pharmacology</i> , 2019, 164, 129-138.	4.4	22
371	Pharmacokinetics of serotonergic drugs: focus on OCD. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 261-273.	3.3	8
372	Treating opioidâ€nduced constipation in patients taking other medications: Avoiding CYP450 drug interactions. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2019, 44, 361-371.	1.5	6

#	ARTICLE	IF	CITATIONS
373	Doseâ€Response Pharmacological Study of Mephedrone and Its Metabolites: Pharmacokinetics, Serotonergic Effects, and Impact of <i>CYP2D6</i> Genetic Variation. Clinical Pharmacology and Therapeutics, 2019, 106, 596-604.	4.7	17
374	Simultaneous quantification of the CYP2D6 substrate yohimbine, its metabolite 11-OH-yohimbine, and the CYP2D6 inhibitor paroxetine in human plasma. Analytical Methods, 2019, 11, 5976-5983.	2.7	1
375	Circulating Extracellular Vesicles Containing Xenobiotic Metabolizing CYP Enzymes and Their Potential Roles in Extrahepatic Cells Via Cellâ€Cell Interactions. International Journal of Molecular Sciences, 2019, 20, 6178.	4.1	28
376	The effect of the CYP2D6 genotype on the maintenance dose of metoprolol in a chronic Dutch patient population. Pharmacogenetics and Genomics, 2019, 29, 179-182.	1.5	7
377	Basic Concepts in Genetics and Pharmacogenomics for Pharmacists. Drug Target Insights, 2019, 13, 117739281988687.	1.4	6
378	Supervised Classification of CYP2D6 Genotype and Metabolizer Phenotype With Postmortem Tramadol-Exposed Finns. American Journal of Forensic Medicine and Pathology, 2019, 40, 8-18.	0.8	8
379	Genotypeâ€sensitive reversible and timeâ€dependent <scp>CYP</scp>2D6 inhibition in human liver microsomes. Basic and Clinical Pharmacology and Toxicology, 2019, 124, 170-180.	2.5	11
380	The Associations Between CYP2D6 Metabolizer Status and Pharmacokinetics and Clinical Outcomes of Venlafaxine: A Systematic Review and Meta-Analysis. Pharmacopsychiatry, 2019, 52, 222-231.	3.3	6
381	Significantly lower CYP2D6 metabolism measured as the <i>O/N</i>â€desmethylenlafaxine metabolic ratio in carriers of <i>CYP2D6*41</i> versus <i>CYP2D6*9</i> or <i>CYP2D6*10</i>: a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients. British Journal of Clinical Pharmacology, 2019, 85, 194-201.	2.4	28
382	Does obtaining CYP2D6 and CYP2C19 pharmacogenetic testing predict antidepressant response or adverse drug reactions?. Psychiatry Research, 2019, 271, 604-613.	3.3	25
383	Changes in tramadol enantioselective pharmacokinetics and metabolism in rats with experimental diabetes treated or not with insulin. European Journal of Pharmaceutical Sciences, 2019, 128, 97-102.	4.0	2
384	Cardiovascular Pharmacogenomics: Does It Matter If You're Black or White?. Annual Review of Pharmacology and Toxicology, 2019, 59, 577-603.	9.4	19
385	CYP2D6 Pharmacogenetics Testing and Postâ€Cesarean Section Pain Scoresâ€a Preliminary Study. Pain Medicine, 2019, 20, 359-368.	1.9	1
386	Phenoconversion of CYP2D6 by inhibitors modifies aripiprazole exposure. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 71-82.	3.2	16
387	Cigarette smoking and heavy coffee consumption affecting response to olanzapine: The role of genetic polymorphism. World Journal of Biological Psychiatry, 2020, 21, 29-52.	2.6	11
388	Genetic Polymorphisms of CYP2D6: Prevalence in Healthy Kurds. Current Pharmacogenomics and Personalized Medicine, 2020, 17, 40-47.	0.2	0
389	Genetic and epigenetic polymorphisms of eNOS and CYP2D6 in mainland Chinese Tibetan, Mongolian, Uyghur, and Han populations. Pharmacogenomics Journal, 2020, 20, 114-125.	2.0	13
390	CYP2D6 genotyping analysis and functional characterization of novel allelic variants in a Ni-Vanuatu and Kenyan population by assessing dextromethorphan O-demethylation activity. Drug Metabolism and Pharmacokinetics, 2020, 35, 89-101.	2.2	9

#	ARTICLE	IF	CITATIONS
391	Advances in Human Induced Pluripotent Stem Cell-Derived Hepatocytes for Use in Toxicity Testing. <i>Annals of Biomedical Engineering</i> , 2020, 48, 1045-1057.	2.5	8
393	Physiologically Based Pharmacokinetic Modelling to Describe the Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone According to Cytochrome P450 2D6 Phenotypes. <i>Clinical Pharmacokinetics</i> , 2020, 59, 51-65.	3.5	15
394	PharmVar GeneFocus: <i>CYP2D6</i> . <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 154-170.	4.7	156
395	Clinical Relevance of CYP2D6 Polymorphisms in Patients of an Austrian Medical Practice: A Family Practice-Based Observational Study. <i>Drugs - Real World Outcomes</i> , 2020, 7, 63-73.	1.6	8
396	CYP2D6 Genotype-guided Metoprolol Therapy in Cardiac Surgery Patients: Rationale and Design of the Pharmacogenetic-guided Metoprolol Management for Postoperative Atrial Fibrillation in Cardiac Surgery (PREEMPTIVE) Pilot Study. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2020, 34, 20-28.	1.3	6
397	ADMET profiling of geographically diverse phytochemical using chemoinformatic tools. <i>Future Medicinal Chemistry</i> , 2020, 12, 69-87.	2.3	41
399	Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across <i>CYP2D6</i> Genotype-Derived Activity Scores. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 678-685.	2.5	13
400	Pharmacogenomics of methadone: a narrative review of the literature. <i>Pharmacogenomics</i> , 2020, 21, 871-887.	1.3	14
401	Allelic and phenotypic characterization of CYP2D6 and its encoded P450 cytochrome enzyme in a series of Spanish type 1 Gaucher disease patients. <i>Medicina Clínica (English Edition)</i> , 2020, 155, 529-534.	0.2	0
402	<i>CYP2D6</i> Predicts Plasma Donepezil Concentrations in a Cohort of Thai Patients with Mild to Moderate Dementia. <i>Pharmacogenomics and Personalized Medicine</i> , 2020, Volume 13, 543-551.	0.7	3
403	Can combination therapy with insulin and metformin improve metabolic function of the liver, in type I diabetic patients? An animal model study on CYP2D1 activity. <i>Journal of Diabetes and Metabolic Disorders</i> , 2020, 19, 2049-2056.	1.9	4
404	In Silico Pharmacogenetics CYP2D6 Study Focused on the Pharmacovigilance of Herbal Antidepressants. <i>Frontiers in Pharmacology</i> , 2020, 11, 683.	3.5	1
405	Pharmacokinetics and pharmacodynamics of dextromethorphan: clinical and forensic aspects. <i>Drug Metabolism Reviews</i> , 2020, 52, 258-282.	3.6	21
406	Influence of <i>CYP2D6</i> *5 and <i>CYP2D6</i> *10 polymorphism on the pharmacokinetics of nebivolol in healthy Chinese subjects. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 632-637.	1.5	6
408	Population Pharmacokinetic Model of Dexmedetomidine in a Heterogeneous Group of Patients. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 1461-1473.	2.0	4
409	Interethnic differences in the prevalence of main cardiovascular pharmacogenetic biomarkers. <i>Pharmacogenomics</i> , 2020, 21, 677-694.	1.3	6
410	Long-Distance Phasing of a Tentative "Enhancer" Single-Nucleotide Polymorphism With CYP2D6 Star Allele Definitions. <i>Frontiers in Pharmacology</i> , 2020, 11, 486.	3.5	10
411	Analysis of the Deleterious Single-Nucleotide Polymorphisms Associated With Antidepressant Efficacy in Major Depressive Disorder. <i>Frontiers in Psychiatry</i> , 2020, 11, 151.	2.6	5

#	ARTICLE	IF	CITATIONS
412	Late-Stage Conversion of a Metabolically Labile Aryl Methyl Ether-Containing Natural Product to Fluoroalkyl Analogues. <i>Journal of Organic Chemistry</i> , 2020, 85, 5416-5427.	3.2	8
413	Assessment of the inhibition risk of paris saponins, bioactive compounds from <i>Paris polyphylla</i> , on CYP and UGT enzymes via cocktail inhibition assays. <i>Regulatory Toxicology and Pharmacology</i> , 2020, 113, 104637.	2.7	1
414	Complete Heart Block Secondary to Flecainide Toxicity: Is It Time for CYP2D6 Genotype Testing?. <i>Pediatrics</i> , 2020, 146, .	2.1	4
415	Oral Yohimbine as a New Probe Drug to Predict CYP2D6 Activity: Results of a Fixed-Sequence Phase I Trial. <i>Clinical Pharmacokinetics</i> , 2020, 59, 927-939.	3.5	8
416	The Systems Biology of Drug Metabolizing Enzymes and Transporters: Relevance to Quantitative Systems Pharmacology. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 40-53.	4.7	29
417	The increasing challenge of the possible impact of ethnicity on psychopharmacology. <i>CNS Spectrums</i> , 2021, 26, 222-231.	1.2	5
418	Impact of genotype-predicted CYP2D6 metabolism on clinical effects and tolerability of metoprolol in patients after myocardial infarction – a prospective observational study. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 673-683.	1.9	12
419	Surface-Bound Humic Acid Increased Propranolol Sorption on Fe ₃ O ₄ /Attapulgite Magnetic Nanoparticles. <i>Nanomaterials</i> , 2020, 10, 205.	4.1	12
420	Cytochrome P450 (CYP450) Interactions Involving Atypical Antipsychotics Are Common in Community-Dwelling Older Adults Treated for Behavioral and Psychological Symptoms of Dementia. <i>Pharmacy (Basel, Switzerland)</i> , 2020, 8, 63.	1.6	7
421	Pharmacokinetic Interactions of a Hop Dietary Supplement with Drug Metabolism in Perimenopausal and Postmenopausal Women. <i>Journal of Agricultural and Food Chemistry</i> , 2020, 68, 5212-5220.	5.2	12
422	Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection. <i>Cmaj</i> , 2020, 192, E450-E453.	2.0	175
423	Added Value of Clinical Sequencing: WGS-Based Profiling of Pharmacogenes. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2308.	4.1	29
424	Repurposing Ophthalmologic Timolol for Dermatologic Use: Caveats and Historical Review of Adverse Events. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 89-99.	6.7	6
425	Considerations When Applying Pharmacogenomics to Your Practice. <i>Mayo Clinic Proceedings</i> , 2021, 96, 218-230.	3.0	22
426	Relative addictive potential of opioid analgesic agents. <i>Pain Management</i> , 2021, 11, 201-215.	1.5	5
427	Conformational Landscape of Cytochrome P450 Reductase Interactions. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1023.	4.1	8
428	Cyrius: accurate CYP2D6 genotyping using whole-genome sequencing data. <i>Pharmacogenomics Journal</i> , 2021, 21, 251-261.	2.0	50
429	Functional phenotyping of the CYP2D6 probe drug codeine in the horse. <i>BMC Veterinary Research</i> , 2021, 17, 77.	1.9	3

#	ARTICLE	IF	CITATIONS
430	No Association Between Pharmacogenomics Variants and Hospital and Emergency Department Utilization: A Mayo Clinic Biobank Retrospective Study. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 229-237.	0.7	7
431	Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. <i>Nature</i> , 2021, 590, 290-299.	27.8	1,069
432	Reversible and Irreversible Inhibition of Cytochrome P450 Enzymes by Methylophiopogonanone A. <i>Drug Metabolism and Disposition</i> , 2021, 49, 459-469.	3.3	21
433	Genetic variability of CYP2D6, CYP3A4 and CYP3A5 among the Egyptian population. <i>Pharmacogenomics</i> , 2021, 22, 323-334.	1.3	6
434	Pharmacogenomics of oxycodone: a narrative literature review. <i>Pharmacogenomics</i> , 2021, 22, 275-290.	1.3	15
435	Attacking COVID-19 Progression Using Multi-Drug Therapy for Synergetic Target Engagement. <i>Biomolecules</i> , 2021, 11, 787.	4.0	14
436	Population Pharmacokinetics of Primaquine in the Korean Population. <i>Pharmaceutics</i> , 2021, 13, 652.	4.5	2
437	Identification of CYP2D6 Haplotypes that Interfere with Commonly Used Assays for Copy Number Variation Characterization. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 577-588.	2.8	10
438	Effects of Genetic Polymorphism in CYP2D6, CYP2C19, and the Organic Cation Transporter OCT1 on Amitriptyline Pharmacokinetics in Healthy Volunteers and Depressive Disorder Patients. <i>Frontiers in Pharmacology</i> , 2021, 12, 688950.	3.5	14
440	Effect of Genetic Polymorphism of the CYP2D6 Gene on the Efficacy and Safety of Fluvoxamine in Major Depressive Disorder. <i>American Journal of Therapeutics</i> , 2021, Publish Ahead of Print, .	0.9	2
441	Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1569-1582.	3.5	11
442	Resolving discordant CYP2D6 genotyping results in Thai subjects: platform limitations and novel haplotypes. <i>Pharmacogenomics</i> , 2021, 22, 529-541.	1.3	10
443	Elimination of Plasmodium vivax Malaria: Problems and Solutions. <i>Infectious Diseases</i> , 0, , .	4.0	5
444	Oxycodone findings and CYP2D6 function in postmortem cases. <i>Forensic Science International: Genetics</i> , 2021, 53, 102510.	3.1	4
445	CYP2D6 Allele Frequency in Five Malaria Vivax Endemic Areas From Brazilian Amazon Region. <i>Frontiers in Pharmacology</i> , 2021, 12, 542342.	3.5	3
446	Classification of drugs for evaluating drug interaction in drug development and clinical management. <i>Drug Metabolism and Pharmacokinetics</i> , 2021, 41, 100414.	2.2	12
447	Cytochrome P450 CYP2D6 genotype-phenotype characterization through population pharmacokinetic modeling of tedatioxetine. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 983-993.	2.5	6
448	Flecainide in Ventricular Arrhythmias: From Old Myths to New Perspectives. <i>Journal of Clinical Medicine</i> , 2021, 10, 3696.	2.4	11

#	ARTICLE	IF	CITATIONS
449	Use of proteomics to identify mechanisms of hepatocellular carcinoma with the CYP2D6*10 polymorphism and identification of ANGPTL6 as a new diagnostic and prognostic biomarker. Journal of Translational Medicine, 2021, 19, 359.	4.4	8
450	Frequency of Important CYP450 Enzyme Gene Polymorphisms in the Iranian Population in Comparison with Other Major Populations: A Comprehensive Review of the Human Data. Journal of Personalized Medicine, 2021, 11, 804.	2.5	7
451	Effects of age and gender on the cytochrome P450 2D6 activity in a Korean population. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 1659-1664.	1.5	1
452	AZD0284, a Potent, Selective, and Orally Bioavailable Inverse Agonist of Retinoic Acid Receptor-Related Orphan Receptor C2. Journal of Medicinal Chemistry, 2021, 64, 13807-13829.	6.4	7
453	Human Three-Dimensional Hepatic Models: Cell Type Variety and Corresponding Applications. Frontiers in Bioengineering and Biotechnology, 2021, 9, 730008.	4.1	12
454	Adverse Drug Reactions of Acetylcholinesterase Inhibitors in Older People Living with Dementia: A Comprehensive Literature Review. Therapeutics and Clinical Risk Management, 2021, Volume 17, 927-949.	2.0	30
455	Differential Interactions of Selected Phytocannabinoids with Human CYP2D6 Polymorphisms. Biochemistry, 2021, 60, 2749-2760.	2.5	9
456	Pharmacist-Led Medication Evaluation Considering Pharmacogenomics and Drug-Induced Phenoconversion in the Treatment of Multiple Comorbidities: A Case Report. Medicina (Lithuania), 2021, 57, 955.	2.0	2
457	Impact of CYP2D6 Polymorphism on Equilibrium Concentration of Fluoxetine in Patients Diagnosed With Major Depressive Disorder and Comorbid Alcohol Use Disorders. Journal of Psychiatric Practice, 2021, 27, 372-379.	0.7	4
458	An Update in Our Understanding of the Relationships Between Gene Polymorphisms and Chemotherapy-Induced Nausea and Vomiting. International Journal of General Medicine, 2021, Volume 14, 5879-5892.	1.8	3
459	A Drug-Drug Interaction Study Evaluating the Effect of Givosiran, a Small Interfering Ribonucleic Acid, on Cytochrome P450 Activity in the Liver. Clinical Pharmacology and Therapeutics, 2021, 110, 1250-1260.	4.7	17
460	The effect of smoking on the plasma concentration of tricyclic antidepressants: a systematic review. Acta Neuropsychiatrica, 2022, 34, 1-9.	2.1	2
461	Pharmacogenetic polymorphisms affecting bisoprolol response. Biomedicine and Pharmacotherapy, 2021, 142, 112069.	5.6	5
462	Human variability in polymorphic CYP2D6 metabolism: Implications for the risk assessment of chemicals in food and emerging designer drugs. Environment International, 2021, 156, 106760.	10.0	16
463	Tobacco Addiction and Psychological Co-morbidities. , 2011, , 207-232.		1
464	Pediatric Chronic Pain. , 2013, , 147-168.		4
465	Pharmacogenomics of Pain Management. , 2013, , 23-33.		5
466	Therapeutic Drug Monitoring of Targeted Anticancer Therapy. Tyrosine Kinase Inhibitors and Selective Estrogen Receptor Modulators: A Clinical Pharmacology Laboratory Perspective. , 2012, , 197-250.		2

#	ARTICLE	IF	CITATIONS
467	CYP2D6: Where It All Began. , 2015, , 29-32.		1
468	Genetic Polymorphisms of Cytochrome P450 and Antidepressants. , 2016, , 533-543.		2
469	Allelic and phenotypic characterization of CYP2D6 and its encoded P450 cytochrome enzyme in a serie of Spanish type 1 Gaucher disease patients. Medicina Clínica, 2020, 155, 529-534.	0.6	2
473	Roles of CYP2C19 Gene Polymorphisms in Susceptibility to POAG and Individual Differences in Drug Treatment Response. Medical Science Monitor, 2016, 22, 310-315.	1.1	6
474	Long read nanopore sequencing for detection of HLA and CYP2D6 variants and haplotypes. F1000Research, 2015, 4, 17.	1.6	55
475	Transfer learning enables prediction of CYP2D6 haplotype function. PLoS Computational Biology, 2020, 16, e1008399.	3.2	32
476	Molecular Dynamics of CYP2D6 Polymorphisms in the Absence and Presence of a Mechanism-Based Inactivator Reveals Changes in Local Flexibility and Dominant Substrate Access Channels. PLoS ONE, 2014, 9, e108607.	2.5	24
477	Distribution of CYP2D6 Alleles and Phenotypes in the Brazilian Population. PLoS ONE, 2014, 9, e110691.	2.5	49
478	Analysis of Genetic Variation in CYP450 Genes for Clinical Implementation. PLoS ONE, 2017, 12, e0169233.	2.5	66
479	Phenotypic differences in nebivolol metabolism and bioavailability in healthy volunteers. Medicine and Pharmacy Reports, 2015, 88, 208-213.	0.4	14
480	Genetic polymorphism of CYP1A1 and CYP2D6 in populations of Buryats, Teleuts and Russians of Eastern Siberia. Vavilovskii Zhurnal Genetiki i Selektzii, 2018, 22, 205-211.	1.1	6
481	Tamoxifen side effects: pharmacogenetic and clinical approach in Mexican mestizos. Translational Cancer Research, 2019, 8, 23-34.	1.0	11
482	Effects of salidroside on rat CYP enzymes by a cocktail of probe drugs. Iranian Journal of Basic Medical Sciences, 2018, 21, 422-426.	1.0	5
483	Evaluation of lentinan effects on cytochrome P450 activity in rats by a cocktail method. Iranian Journal of Basic Medical Sciences, 2019, 22, 296-301.	1.0	4
485	Pharmacogenetics and Psychiatric Care: A Review and Commentary. Journal of Mental Health and Clinical Psychology, 2018, 2, 17-24.	0.5	19
486	Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations. Dialogues in Clinical Neuroscience, 2016, 18, 323-337.	3.7	38
487	Schizophrenia and Smoking. Journal of Clinical Psychiatry, 2012, 73, e725-e727.	2.2	6
488	A Prospective Study to Evaluate the Effect of CYP2D6 Polymorphism on Plasma level of Risperidone and its Metabolite in North Indian Patients with Schizophrenia. Indian Journal of Psychological Medicine, 2018, 40, 335-342.	1.5	6

#	ARTICLE	IF	CITATIONS
489	Is Pharmacogenomics Ready for Prime Time?. Journal of Pharmacogenomics & Pharmacoproteomics, 2012, 03, .	0.2	2
490	Antipsychotic Medication and Risk of QTc Prolongation: Focus on Multiple Medication and Role of Cytochrome P450 Isoforms. Open Journal of Psychiatry, 2014, 04, 381-389.	0.6	1
491	Prevalence of CYP2D6 Genotypes and Predicted Phenotypes in a Cohort of Cambodians at High Risk for Infections with Plasmodium vivax. American Journal of Tropical Medicine and Hygiene, 2020, 103, 756-759.	1.4	12
492	CYP2D6 P34S Polymorphism and Outcomes of Escitalopram Treatment in Koreans with Major Depression. Psychiatry Investigation, 2013, 10, 286.	1.6	16
493	ER/LA opioid REMS supplement. Journal of Opioid Management, 2023, 10, 1-48.	0.5	3
494	Harnessing pharmacological knowledge for personalized medicine and pharmacotyping: Challenges and lessons learned. World Journal of Pharmacology, 2014, 3, 110.	2.3	2
495	Topics on Drug Metabolism. , 2012, , .		9
496	Genetic Variants of CYP2D6 Gene and Cancer Risk: A HuGE Systematic Review and Meta-analysis. Asian Pacific Journal of Cancer Prevention, 2012, 13, 3165-3172.	1.2	14
497	Polymorphism of the cytochrome P450 CYP1A1 (Ile462Val) gene in the populations of Balkars and Karachays. Ecological Genetics, 2021, 19, 273-279.	0.5	1
498	Could Cytochrome P450 2D6, 3A4 and 3A5 Polymorphisms Explain the Variability in Clinical Response to Clomiphene Citrate of Anovulatory PCOS Women?. Frontiers in Endocrinology, 2021, 12, 718917.	3.5	2
499	Drug metabolism in animal models and humans: Translational aspects and chances for individual therapy. Acta Physiologica, 2021, 233, e13734.	3.8	3
500	Generation of Caco-2 cells stably expressing CYP3A4&PORA&UGT1A1 and&CYP3A4&PORA&UGT1A1*6& using a PITCH _{4.2} system. Archives of Toxicology, 2022, 96, 499-510.	4.2	4
501	Conditions for maintenance of hepatocyte differentiation and function in 3D cultures. IScience, 2021, 24, 103235.	4.1	8
502	Pharmacogenetics of Cytochrome P450 2D6: A Translational Medicine Perspective. The Open Conference Proceedings Journal, 2010, 1, 103-108.	0.6	0
504	A Case of Interdose Discontinuation Symptoms With Venlafaxine Extended Release. primary care companion for CNS disorders, The, 2011, 13, .	0.6	2
506	The Pharmacogenomics of Cytochrome P450s: From Molecular to Clinical Application. , 2014, , 345-370.		1
507	Pharmacogenomics"Pharmacoeigenomics of Breast Cancer Therapy: Clinical Implications. , 2014, , 499-518.		0
509	Psychotropic Medications: Optimal Prescribing Through the Utilization of Genetic Testing. Journal of Psychology & Clinical Psychiatry, 2014, 1, .	0.1	0

#	ARTICLE	IF	CITATIONS
510	Pharmacogenomics of Pain Management. , 2015, , 21-31.		2
511	Role of oxidative stress in genesis of endometriosis. Reproductive Endocrinology, 2014, .	0.3	1
512	Culture-Specific Characteristics of Alcohol Related Disorders and Culture- Sensitive Approach in Ethiopian Immigrants and Ethnic Arabic Groups in Israel. , 2015, 04, .		0
513	Concepts of Anticancer Treatment and Pharmacogenomics in Cancer Treatments. , 2015, , 64-114.		0
514	Essential Pharmacogenomic Biomarkers in Clinical Practice. , 2016, , 51-74.		0
515	Precision medicine for managing chronic diseases. Polish Archives of Internal Medicine, 2016, 126, 681-687.	0.4	5
516	Opioids and Related Medications. , 2017, , 165-190.		0
517	Pharmacogenetics of Pain: The Future of Personalized Medicine. , 2018, , 435-445.		0
519	Antipsychotic Drug Interactions. Current Clinical Psychiatry, 2020, , 277-287.	0.2	0
520	Genetic polymorphism leading to drug overdose fatality while in custody. , 2020, , 113-116.		0
521	Effect of <i>CYP2D6</i> genetic polymorphism on peak propafenone concentration: no significant effect of <i>CYP2D6*10</i> . Pharmacogenomics, 2020, 21, 1279-1288.	1.3	3
522	Prescription de tramadol chez les enfants : une bonne alternative À la codéine ? Douleur Et Analgesie, 2020, 33, 247-256.	0.1	0
523	Clinical response to cholinesterase inhibitors in dementia. , 2020, , 89-102.		0
524	Pharmacokinetics and Pharmacodynamics. , 2020, , 27-56.		0
526	Personalized Medicine and Perioperative Stress Response Modification. , 2021, , 291-302.		0
527	Farmacogenômica e Doença Cardiovascular: Onde Estamos e Para Onde Vamos. Arquivos Brasileiros De Cardiologia, 2020, 115, 690-700.	0.8	0
529	Novel pathway analysis of genomic polymorphism-cancer risk interaction in the Breast Cancer Prevention Trial. International Journal of Molecular Epidemiology and Genetics, 2010, 1, 332-49.	0.4	13
532	ELIGLUSTAT TARTRATE: Glucosylceramide Synthase Inhibitor Treatment of Type 1 Gaucher Disease. Drugs of the Future, 2010, 35, 613-620.	0.1	42

#	ARTICLE	IF	CITATIONS
533	Cytochrome P450 enzyme mediated herbal drug interactions (Part 1). EXCLI Journal, 2014, 13, 347-91.	0.7	71
534	Cytochrome P450-2D6 Genotype Definition May Improve Therapy for Paroxysmal Atrial Fibrillation A Case of Syncope Following "Pill-in-the-Pocket" Quinidine plus Propafenone. Journal of Atrial Fibrillation, 2014, 6, 978.	0.5	2
535	Automated Metabolic Phenotyping of Cytochrome Polymorphisms Using PubMed Abstract Mining. AMIA ... Annual Symposium proceedings, 2017, 2017, 535-544.	0.2	2
536	Pharmacogenetics and Psychiatric Care: A Review and Commentary. , 2018, 2, 17-24.		8
537	Impact of Polymorphism of CYP2D6 on Equilibrium Concentration of Duloxetine in Patients Suffering from Major Depressive Disorder. Psychopharmacology Bulletin, 2020, 50, 47-57.	0.0	1
538	The Influence of Concentration of Micro-RNA hsa-miR-370-3p and CYP2D6*4 on Equilibrium Concentration of Mirtazapine in Patients With Major Depressive Disorder. Psychopharmacology Bulletin, 2020, 50, 58-75.	0.0	3
539	Impact of the Omics-Based Biomarkers on the Fluvoxamine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder. Psychopharmacology Bulletin, 2021, 51, 69-80.	0.0	0
540	Impact of the Omics-Based Biomarkers on the Mirtazapine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder. Psychopharmacology Bulletin, 2021, 51, 31-42.	0.0	0
541	Customizable Microfluidic Origami Liver-on-a-Chip (oLOC). Advanced Materials Technologies, 2022, 7, 2100677.	5.8	9
542	Arzneimitteltherapiesicherheit: Interaktionspotenzial der Antiemetika. , 0, , .		0
543	Ten Years of Experience Support Pharmacogenetic Testing to Guide Individualized Drug Therapy. Pharmaceutics, 2022, 14, 160.	4.5	0
544	The Mechanism of Ajmaline and Thus Brugada Syndrome: Not Only the Sodium Channel!. Frontiers in Cardiovascular Medicine, 2021, 8, 782596.	2.4	6
545	Influence of Plasma Concentration of Hsa-Mir-370-3p and Cyp2d6*4 On Equilibrium Concentration of Phenazepam in Patients with Recurrent Depressive Disorder. Psychopharmacology Bulletin, 2021, 51, 87-104.	0.0	0
546	The influence of concentration of micro-rna hsa-mir-370-3p and CYP2D6*4 on equilibrium concentration of mirtazapine in patients with major depressive disorder. European Psychiatry, 2021, 64, S454-S455.	0.2	2
547	Therapeutic drug monitoring in children and adolescents with schizophrenia and other psychotic disorders using risperidone. Journal of Neural Transmission, 2022, 129, 689-701.	2.8	6
549	Drug Transporters ABCB1 (P-gp) and OATP, but not Drug-Metabolizing Enzyme CYP3A4, Affect the Pharmacokinetics of the Psychoactive Alkaloid Ibogaine and its Metabolites. Frontiers in Pharmacology, 2022, 13, 855000.	3.5	2
550	Therapeutic drug monitoring of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: a naturalistic study. Journal of Neural Transmission, 2022, , 1.	2.8	3
551	Frequency of CYP2D6*3 and *4 and metabolizer phenotypes in three mestizo Peruvian populations. Pharmacia, 2021, 68, 891-898.	1.2	4

#	ARTICLE	IF	CITATIONS
552	Effects of CYP2D6 Genetic Polymorphism and Drug Interaction on the Metabolism of Dacomitinib. <i>Chemical Research in Toxicology</i> , 2022, 35, 265-274.	3.3	4
558	An Updated Review of Genetic Associations With Severe Adverse Drug Reactions: Translation and Implementation of Pharmacogenomic Testing in Clinical Practice. <i>Frontiers in Pharmacology</i> , 2022, 13, 886377.	3.5	14
559	Drug Interactions Affecting Antiarrhythmic Drug Use. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2022, 15, 101161CIRCEP121007955.	4.8	6
560	Inhibitory effects of fluoxetine and duloxetine on the pharmacokinetics of metoprolol in vivo and in vitro. <i>Fundamental and Clinical Pharmacology</i> , 2022, 36, 1057-1065.	1.9	2
561	Influence of CYP2D6 genetic variation on adverse events with propafenone in the pediatric and young adult population. <i>Clinical and Translational Science</i> , 2022, 15, 1787-1795.	3.1	1
563	Analysis of inter-individual variability of antitussive effect of Farfarae Flos and its fecal metabolites based on gut microbiota. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2022, 217, 114836.	2.8	3
564	Recommendations for oral treatment for adult patients with type 1 Gaucher disease. <i>Revista Colombiana Espanola</i> , 2022, , .	0.5	0
565	A Potential Drug-Gene-Drug Interaction Between Cannabidiol, CYP2D6*4, and Fluoxetine. <i>Journal of Clinical Psychopharmacology</i> , 2022, 42, 422-424.	1.4	5
566	Pharmacogenomic Profile of Amazonian Amerindians. <i>Journal of Personalized Medicine</i> , 2022, 12, 952.	2.5	1
567	Strategies for developing Alzheimer's disease treatments: application of population pharmacokinetic and pharmacodynamic models. <i>Journal of Pharmaceutical Investigation</i> , 2022, 52, 519-538.	5.3	2
568	Physiologically-Based Pharmacokinetic Models of CYP2D6 Substrate and Inhibitors Nebivolol, Cinacalcet and Mirabegron to Simulate Drug-Drug Interactions. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 0, , .	1.6	1
569	The Effect of CYP2D6 Phenotypes on the Pharmacokinetics of Propafenone: A Systematic Review and Meta-Analysis. <i>Pharmaceutics</i> , 2022, 14, 1446.	4.5	2
570	Plasma exchange treats severe intrahepatic cholestasis caused by dacomitinib: A case report. <i>Medicine (United States)</i> , 2022, 101, e29629.	1.0	1
571	The effect of anlotinib on the pharmacokinetic profile of oxycodone and the underlying mechanism. <i>Chemico-Biological Interactions</i> , 2022, 364, 110044.	4.0	1
572	Bioactivation and Reactivity Research Advances – 2021 year in review. <i>Drug Metabolism Reviews</i> , 0, , 1-83.	3.6	0
573	Hiccups induced by aripiprazole combined with sertraline in an adolescent with olfactory reference disorder: A case report. <i>Frontiers in Psychiatry</i> , 0, 13, .	2.6	2
574	Isolation and Identification of 3,4-Seco-Solanidine-3,4-dioic Acid as a Urinary Biomarker of CYP2D6 Activity. <i>Drug Metabolism and Disposition</i> , 2022, 50, 1342-1351.	3.3	7
575	Pharmacogenetic profiling and individualised therapy in the treatment of degenerative spinal conditions. <i>Irish Journal of Medical Science</i> , 0, , .	1.5	1

#	ARTICLE	IF	CITATIONS
576	Pharmacogenomics of Opioid Treatment for Pain Management. <i>Methods in Molecular Biology</i> , 2022, , 491-504.	0.9	0
577	The impact of CYP2D6*41 on CYP2D6 enzyme activity using phenotyping methods in urine, plasma, and saliva. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	1
578	Potential Inhibitory and Inducing Effects of Triphala Formulation on Cytochrome P450 Enzymes. <i>Trends in Sciences</i> , 2022, 19, 5819.	0.5	0
579	Pharmacogenomics in Psychiatry Practice: The Value and the Challenges. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13485.	4.1	5
580	Cytochrome P450 Genes: Their Role in Drug Metabolism and Violence. , 2022, , 1-29.		0
581	Delineating geneâ€environment effects using virtual twins of patients treated with clozapine. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2023, 12, 168-179.	2.5	8
582	Factors Influencing Pharmacokinetics of Tamoxifen in Breast Cancer Patients: A Systematic Review of Population Pharmacokinetic Models. <i>Biology</i> , 2023, 12, 51.	2.8	2
583	Pharmacokinetic and pharmacogenomic considerations in managing use of nirmatrelvir-ritonavir and molnupiravir and dermatological treatments. <i>Annals of the Academy of Medicine, Singapore</i> , 2022, 51, 752-754.	0.4	1
584	Association of cytochrome P450 2D15 (CYP2D15) nonsynonymous polymorphisms and exon 3 deleted RNA splice variant with CYP2D15 protein content and enzyme function in dog liver microsomes. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , 2023, 46, 77-90.	1.3	3
585	Pharmacokinetics of Tamoxifen and Its Major Metabolites and the Effect of the African Ancestry Specific CYP2D6*17 Variant on the Formation of the Active Metabolite, Endoxifen. <i>Journal of Personalized Medicine</i> , 2023, 13, 272.	2.5	6
586	Discovery of Clinical Candidate ACT-777991, a Potent CXCR3 Antagonist for Antigen-Driven and Inflammatory Pathologies. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 4179-4196.	6.4	5
587	Recombinant Technologies Facilitate Drug Metabolism, Pharmacokinetics, and General Biomedical Research. <i>Drug Metabolism and Disposition</i> , 2023, 51, 685-699.	3.3	5
588	Neonatology for Anesthesiologists. , 2017, , 513-570.e15.		0
589	Precision medicine: Overview and challenges to clinical implementation. , 2023, , 513-529.		0
590	HepaSH cells: Experimental human hepatocytes with lesser inter-individual variation and more sustainable availability than primary human hepatocytes. <i>Biochemical and Biophysical Research Communications</i> , 2023, 663, 132-141.	2.1	4
591	Precision Medicine in Antidepressants Treatment. <i>Handbook of Experimental Pharmacology</i> , 2023, , .	1.8	0
592	Physiology and Development of the Term and Preterm Neonate. , 2023, , 19-98.		0
593	Case report: Use of therapeutic drug monitoring and pharmacogenetic testing as opportunities to individualize care in a case of flecainide toxicity after fetal supraventricular tachycardia. <i>Frontiers in Pediatrics</i> , 0, 11, .	1.9	0

#	ARTICLE	IF	CITATIONS
594	INVESTIGATION OF SUPERFLUITY POTENTIAL OF BCS-II DRUG BY USING SOLVENT SHIFT METHOD. Indian Drugs, 2023, 60, 83-89.	0.1	0
595	Therapeutic difficulties in a patient with Ehlers-Danlos syndrome and numerous symptomatic premature ventricular contractionsâ€”case report and literature review. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	0
596	Cytochrome P450 Genes: Their Role in Drug Metabolism and Violence. , 2023, , 1519-1546.		0
597	Multivalency-enhanced enzyme inhibitors with biomolecule-responsive activity. Biomaterials Science, 2023, 11, 6770-6774.	5.4	0
598	Effect of apatinib on the pharmacokinetics of tramadol and O-desmethyltramadol in rats. PeerJ, 0, 11, e16051.	2.0	1
599	Pharmacological Treatments and Therapeutic Drug Monitoring in Patients with Chronic Pain. Pharmaceutics, 2023, 15, 2088.	4.5	2
600	Hydrocodone, Oxycodone, and Morphine Metabolism and Drugâ€™Drug Interactions. Journal of Pharmacology and Experimental Therapeutics, 2023, 387, 150-169.	2.5	2
601	Impact of amiodarone use on metoprolol concentrations, <sc>Î±â€™OH</sc>â€™metoprolol concentrations, metoprolol dosing and heart rate: A crossâ€™sectional study. Pharmacology Research and Perspectives, 2023, 11, .	2.4	0
602	Depressive disorders and their pharmacotherapy in routine clinical practice. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2023, 15, 54-64.	1.2	0
603	The roles of <sc>CYP2C19</sc> and <sc>CYP3A4</sc> in the inâ€™vitro metabolism of Î²â€™udesmol in human liver: Reaction phenotyping and enzyme kinetics. Pharmacology Research and Perspectives, 2023, 11, .	2.4	0
604	Theâ€™Use of Timolol for Wound Healingâ€™A Review. Current Dermatology Reports, 2024, 13, 8-27.	2.1	0